{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:29:40Z","timestamp":1775791780281,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of luteinizing hormone (LH) in controlled ovarian hyperstimulation (COH) requires more evidence for its efficacy. Several studies compared recombinant human LH (r-hLH) or human menopausal gonadotropin (hMG) in combination with recombinant human follicle-stimulating hormone (r-hFSH) but lack the results with GnRH-antagonist protocol and in Asians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a retrospective, single-center study inspecting women receiving GnRH antagonist protocol and r-hFSH+hMG or r-hFSH+r-hLH regimen for over five days for COH in the\n                      <jats:italic>in vitro<\/jats:italic>\n                      fertilization (IVF)\/intracytoplasmic sperm injection (ICSI) cycle in Taiwan from 2013 to 2018. The outcomes of IVF\/ICSI cycles were analyzed after propensity score matching between the two groups. A subgroup analysis was conducted in cycles in which women underwent their first embryo transfer (ET), including fresh ET and frozen ET (FET).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a total of 503 cycles, the results revealed that the r-hFSH+r-hLH group performed better in terms of numbers of oocytes retrieved (r-hFSH+hMG vs. r-hFSH+r-hLH, 11.7 vs. 13.7, p=0.014), mature oocytes (8.7 vs. 10.9, p=0.001), and fertilized oocytes (8.3 vs. 9.8, p=0.022), while other outcomes were comparable. The analysis of first ET cycles also showed similar trends. Although the implantation rate (39% vs. 43%, p=0.37), pregnancy rate (52% vs. 53%, p=0.90), and live birth rate (39% vs. 45%, p=0.19) were not significantly different, the miscarriage rate was higher in the r-hFSH+hMG group than the r-hFSH+r-hLH group (26% vs. 15%, p&amp;lt;0.05) in first ET cycles. The cumulative live birth rate was significantly higher in the r-hFSH+r-hLH group (53% vs. 64%, p=0.02). No significant difference in rates of ovarian hyperstimulation syndrome (OHSS) was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results support the hypothesis that the treatment of r-hLH+r-hFSH improves COH clinical outcomes in the IVF\/ICSI cycle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.931756","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:46:16Z","timestamp":1660524376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol"],"prefix":"10.3389","volume":"13","author":[{"given":"Ming-Jer","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chiao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Fen","family":"Guu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Fan","family":"Kung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ting","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1477-7827-12-109","article-title":"Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization\/intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: A systematic review and meta-analysis","volume":"12","author":"Xiong","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.01.003","article-title":"Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review","volume":"109","author":"Alviggi","year":"2018","journal-title":"Fertil Steril"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00282","article-title":"An observational retrospective cohort trial on 4,828 IVF cycles evaluating different low prognosis patients following the poseidon criteria","volume":"10","author":"Levi-Setti","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12958-019-0460-4","article-title":"The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: A systematic review and meta-analysis","volume":"17","author":"Conforti","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2020.08.035","article-title":"Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: A large, real-world study","volume":"42","author":"Arvis","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(10)62071-8","article-title":"Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification some its major impurities","volume":"7","author":"Van de Weijer","year":"2003","journal-title":"Reprod BioMed Online"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000308458","article-title":"Clinical efficacy of highly purified hMG versus recombinant FSH in IVF\/ICSI cycles: A meta-analysis","volume":"70","author":"Jee","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD005354","DOI":"10.1002\/14651858.CD005354.pub2","article-title":"Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles","author":"Van Wely","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-015-0080-6","article-title":"Controlled ovarian stimulation with recombinant-FSH plus recombinant-LH vs. human menopausal gonadotropin based on the number of retrieved oocytes: Results from a routine clinical practice in a real-life population","volume":"13","author":"Revelli","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deu302","article-title":"Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women \u226535 years: A RCT","volume":"30","author":"Moro","year":"2015","journal-title":"Hum Reprod"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.04.035","article-title":"Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: A multicenter, prospective, randomized controlled trial","volume":"94","author":"Pacchiarotti","year":"2010","journal-title":"Fertil Steril"},{"key":"B12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3275\/8657","article-title":"Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: Clinical evidences of human recombinant FSH\/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimula","volume":"35","author":"Carone","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-017-1034-z","article-title":"Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve","volume":"34","author":"Mignini Renzini","year":"2017","journal-title":"J Assist Reprod Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2013.10.027","article-title":"A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: A retrospective analysis","volume":"172","author":"Dahan","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(10)61131-5","article-title":"LH improves early follicular recruitment in women over 38 years old","volume":"11","author":"G\u00f3mez-Palomares","year":"2005","journal-title":"Reprod BioMed Online"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2011.633128","article-title":"Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: A matched case-control study","volume":"28","author":"B\u00fchler","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0175985","article-title":"Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis","volume":"12","author":"Wang","year":"2017","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD001750","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00114","article-title":"Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the \u201cpersonalized\u201d medicine era: A meta-analysis","volume":"8","author":"Santi","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1201\/b14639-8","volume-title":"An atlas of human gametes and conceptuses: An illustrated reference for assisted reproductive technology","author":"Veeck","year":"1999"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2017.10.013","article-title":"Does the \u201cfreeze-all\u201d policy allow for a better outcome in assisted reproductive techniques than the use of fresh embryo transfers? \u2013 A retrospective study on cumulative live birth rates","volume":"56","author":"Chang","year":"2017","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e46682","DOI":"10.1016\/bs.pmbts.2016.08.002","article-title":"LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling","volume":"7","author":"Casarini","year":"2012","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00065","article-title":"Two hormones for one receptor: Evolution, biochemistry, actions, and pathophysiology of LH and hCG","volume":"39","author":"Casarini","year":"2018","journal-title":"Endocr Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev038","article-title":"Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged \u226535 years: A randomized controlled trial","volume":"30","author":"Vuong","year":"2015","journal-title":"Hum Reprod"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2016.11.014","article-title":"Effect of mid-follicular phase recombinant LH versus urinary HCG supplementation in poor ovarian responders undergoing IVF \u2013 A prospective double-blinded randomized study","volume":"34","author":"Mak","year":"2017","journal-title":"Reprod BioMed Online"},{"key":"B26","article-title":"Correlation of the day 3 FSH\/LH ratio and LH concentration in predicting IVF outcome","volume":"14","author":"Prasad","year":"2013","journal-title":"J Reprod Infertil"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.28982\/josam.666963","article-title":"High basal LH levels are associated with improved cycle outcomes of assisted reproduction","volume":"4","author":"Tokg\u00f6z","year":"2020","journal-title":"J Surg Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.202100406R","article-title":"Outcomes comparison of IVF\/ICSI among different trigger methods for final oocyte maturation: A systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"FASEB J"}],"updated-by":[{"DOI":"10.3389\/fendo.2022.1099647","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.931756\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T07:15:10Z","timestamp":1670397310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.931756\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":28,"alternative-id":["10.3389\/fendo.2022.931756"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.931756","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742305266.793595219","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"931756"}}